Imugene Limited (ASX:IMU)

There is expected to be a great deal of news flow from Imugene (ASX: IMU) as it looks to quickly attract the attention of a big pharma partner looking to bring effective cancer treatments to market.

The $33 million-capped IMU is currently developing immuno-oncology therapies and is moving ahead at a significant pace, having recently received notice that the Canadian Patent Office had issued a Grant Notice for this next generation cancer therapy that will protect specific cancer vaccination formulations for commercial interest.

IMU’s frontrunner drug candidate HER-Vaxx, is already in Phase 1b and Phase 2 trials and is interestingly further advanced than Regeneron’s cancer therapies before Regeneron was  acquired for $1.6 billion by Roche.

IMU is looking to attract big pharma’s attention by 2020.

HER-Vaxx targets the same receptor as the two leading antibody drugs on the market, Herceptin and Perjeta, with annual sales of US$8.2 billion in a markety predicted to generate sales of US$36 billion by 2025.

IMU is looking to commercialise a treatment that has improved efficacy over existing treatments and is more cost efficient, which would give it a strong position in this market.

The information in this email should not be the only trigger for your investment decision. Click on the link below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.

HER-Vaxx isn’t IMU’s only play here. It is also working with Arginine, a critical amino acid for the health of cancer fighting T-cells.

Again, IMU will be looking to replicate recent deals done in the space including a deal struck recently between $25 billion-capped Incyte and Calithera Biosciences in which $53 million was paid up front by Incyte.

As IMU is working off the same premise, could we see this $37.8 million capped company climb higher?

Latest Article

IMU Picks up the Pace in Cancer Drug Treatment Development

IMU Picks up the Pace in Cancer Drug Treatment Development

It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing. These therapies, if proven safe and successful, could have an undeniable real world positive effect for cancer patients.


Related Imugene Limited (ASX:IMU) articles

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?

One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.


Top Trending